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Abstract
Venous gangrene (VG) is defined as a clinical triad of skin necrosis and discolouration, documented
evidence of venous thromboembolism (VTE) and presence of palpable or doppler- identifiable
arterial pulsation. Venous gangrene is rare condition which is associated with poor prognosis in
cancer patients. The pathogenesis of VG is multifactorial and could paradoxically be due to warfarin
treatment. Heparin Induced Thrombocytopenia (HIT) associated venous gangrene develops when
heparin therapy is discontinued and warfarin therapy initiated or continued.
It has been reported that the presence of anticardiolipin antibodies appears to double the risk of
thrombo-embolic events in cancer patients in comparison with those who are anticardiolipin
antibody negative. The presence of anticardiolipin antibodies is therefore a warning sign for venous
gangrene in cancer patients. Hypercoagulable state associated with malignancy, cancer treatment,
prolonged immobilisation, surgical operations and metabolic syndrome are all associated with
increased risk of VTE and VG.
The current evidence suggests that cancer patients are at increased risk from recurrent venous
thrombosis and venous gangrene, and LMWH provides potential promise as a safe and effective
measure in the management of such patients.
Background
Venous gangrene (VG) is a rare condition in association
with malignancy but carries a grave prognosis [1]. Venous
gangrene does not occur in isolation of VTE. Patients with
cancer have long been recognised to be at a high risk of
venous thromboembolism, nevertheless the condition
remains under-diagnosed and under-treated in these
patients. In consequence, the morbidity and mortality due
to thromboembolism remains unacceptably high. Fur-
thermore, the management of such patients in the pres-
ence of malignancy is complex, due to the effects of cancer
itself and its treatments [1,2].
Interestingly, VG could paradoxically be due to warfarin
treatment in association with decreased level of protein C
[3]. The epidemiology, pathogensis and management of
cancer-related venous gangrene are discussed in this
review.
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Currently the incidence of VG in association with cancer
is not well established. However, there are a few reported
cases in the literature showing that VG is always in associ-
ation with venous thrombo-embolism (VTE). The annual
incidence of VTE in a cancer population is 500 in 100,000
(one in two-hundred) in comparison with 117 in 100,000
in the general population [1,4]. Rates of VTE as high as
43% in patients with metastatic renal cell carcinoma
receiving chemotherapy has been reported [5]. In an anal-
ysis of the autopsy records of 157 cases with carcinoma of
the pancreas, venous thromboembolism was found in
50% of patients at post-mortem examination [6].
In their study of 1041 patients with solid tumours admit-
ted to 3 major medical centres in the USA, Sallah et al
found the highest rates of VTE in cases of advanced malig-
nancies, renal carcinoma, pancreatic, gastric and brain
tumours. Leading the view that mucin-producing
tumours are most often strongly associated with the
occurrence of venous thrombosis [7]. However, the most
common malignancies associated with thrombosis are
those of the breast, colon and lung, reflecting the preva-
lence of these malignancies in the general population [1].
Further research is needed to establish the incidence of VG
in association with cancer.
Pathogenesis
The pathogenesis of (VG) is obscure; however, venous
gangrene does not occur in isolation of venous throm-
boembolism. Venous gangrene could paradoxically be
due to warfarin treatment and develop when the interna-
tional randomised ratio (INR) is above 6.0, therapeutic
range (2.0–3.0). At this supra- therapeutic level of INR the
level of protein C is markedly decreased but the thrombin-
antithrombin complexes remain unexplainably high [3].
This profound disturbance in procoagulant-anticoagulant
balance during warfarin treatment leads to progressive
microvascular thrombosis secondary to acquired natural
anticoagulant depletion during warfarin therapy. In addi-
tion, warfarin anticoagulation can cause paradoxical
thrombotic events, particularly central skin necrosis of the
breasts, abdomen and thighs in patients with congenital
heterozygous protein C deficiency [8,9]. It has been pos-
tulated that warfarin-induced skin necrosis is caused by a
transient prothrombotic state that results from a faster
reduction in the level of the major natural anticoagulant
factor (protein C; half-life, 6 hours) than in the level of the
major procoagulant factor (prothrombin; half-life, 72
hours) [10].
Furthermore, in a study of 158 patients with heparin-
induced thrombocytopenia (HIT), 8 patients developed
acute venous limb gangrene after heparin therapy was dis-
continued and warfarin therapy either initiated or contin-
ued. In these 8 patients the INR level was at suprat-
herpeutic [10,11]. HIT is caused by a platelet-activating,
heparin-dependent IgG antibody and is an important
cause of paradoxical arterial and venous thrombotic com-
plications. It is suggested that a warfarin-induced failure
of the protein C anticoagulant pathway to regulate the
increased thrombin generation that occurs in patients
with heparin-induced thrombocytopenia, that leads to
venous thrombosis and gangrene[12-14].
Antiphosolipid antibodies may also be responsible for the
increased venous thrombosis in cancer patients. Anti-
phospholipids antibodies are mainly composed of the
lupus anticoagulant and anticardiolipin antibodies. These
antibodies predispose to thrombosis either by interacting
with phospholipids in the platelets and the vascular
endothelium or by inhibiting protein C activation and
prostacyclin formation in the endothelial cells. It has been
reported that the presence of anticardiolipin antibodies
appears to double the risk of thrombo-embolic events in
cancer patients in comparison with those who are anticar-
diolipin antibody negative (28% versus 14%) [1,15].
The hypercoagulable state associated with malignancy is
thought to be due to: direct activation of clotting system
by cancer cells, and indirectly by activation of platelets,
monocyte and endothelial cells. Cytokines such as
tumour necrosis factor-α (TNF-α) and interleukin-1β
released by tumour cells activate the tissue factor (TF).
This transmembrane protein which found only on fibrob-
lasts of vascular adventitia and other stromal cells is also
expressed on the surfaces of all solid tumour cells. It initi-
ates coagulation by binding to activated factor VII.
Cytokines increase the expression of TF and platelets acti-
vating factors (PAF) and decrease the expression of throm-
bomodulin and the endothelial cells protein C receptors.
This imbalance in procoagulant-anticoagulant pathways
leads to the hypercoagulable state associated with malig-
nancy leading to the increased risk of thrombosis in can-
cer patients. In addition, decreased levels of antithrombin
III, deficiency of protein C and S were reported with can-
cer [16-19]. Significantly, cancer treatment especially
chemotherapy and hormonal therapy such as tamoxifen
significantly contributes to the increased risk of thrombo-
sis in cancer patients [20].
Immobilisation, prolonged bed rest, dehydration and
vomiting also significantly increase risk of thromo-embo-
lism [1,2]. In addition, patients undergoing surgery for
cancer have a higher risk of postoperative deep vein
thrombosis (DVT) than those having surgery for non-
malignant disease. After surgery, cancer patients have
twice the risk of DVT and over 3 times the risk of fatal pul-
monary embolism (PE) compared with patients free of
cancer [21,22].Page 2 of 5
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metabolic syndrome and the increased tendency towards
hypercoagualtion in general population [23,24]. The clus-
tering of insulin resistance, dysglycemia, dyslipidemia,
hypertension and central obesity represent the major fea-
tures of metabolic syndrome. The metabolic syndrome
appears to affect between 10 and 25% of adult popula-
tions worldwide [25]. Recently, Kikura et al demonstrated
that features of the metabolic syndrome are risk factors for
perioperative arterial or venous thromboembolism events
and subsequent death within 30 postoperative days in a
total of 21,903 surgical patients followed for 11 years
[26].
Taking all these factors into consideration, it is possible to
postulate that the presence of metabolic syndrome, cancer
and paradoxical effect of warfarin may enhance the proc-
ess of DVT formation and this ultimately may have lead to
venous gangrene in cancer patients (table 1).
Prevention and management of venous 
gangrene
The prevention of venous gangrene is similar to that of
VTE. Attention to good nutrition, hydration and early
ambulation are of paramount importance in cancer
patients (table 2). Use of prophylactic LMWH or unfrac-
tionated heparin (UFH) perioperatively together with
graduated compression stocking reduces the incidence of
postoperative DVT significantly. LMWHs are convenient,
efficacious and safe compared with UFH and coumarin
derivatives and are becoming the anticoagulant class of
choice in surgical and medical oncology patients. Extend-
ing prophylaxis with LMWH beyond hospitalization after
curative open surgery for abdominal or pelvic cancer for
three weeks to four weeks in cancer patients has shown to
reduce the rate of VTE by up to 62% in one study and to
none in another study [27,28]. (Table 2)
In contrast, Andtbacka et al, in their retrospective study of
3898 patients with breast cancer, who underwent 4416
surgical procedures for different stages of breast cancer
concluded that the risk of VTE following breast cancer sur-
gery is rare (rate of 0.16 per procedure). This lower rate of
VTE was achieved by adherence to their clinical pathway
using mechanical antithrombotic devices and early ambu-
lation in the postoperative period, without the need for
systemic VTE prophylaxis in the form of LMWHs [29].
The conventional treatment of VTE is to start with thera-
peutic dose of LMWH, followed by warfarin to attain an
INR of 2–3 for six months or warfarin for life in cases of
recurrent VTE. This regime is very effective in patients
without cancer. However, the use of vitamin K antagonist
to treat thrombosis in cancer patients is associated with 3-
fold increase in the risk of recurrent VTE and up to 6-fold
increase in the risk of major bleeding in comparison with
non-cancer patients [1]. Furthermore, difficulties in main-
taining the international normalized ratio (INR) within
the therapeutic range due to drug interactions, treatment
interruption as a result of illness and invasive procedures
(e.g. central line insertion) are common problems in
patients with cancer. If warfarin have to be used in cancer
patients with VTE for long-term anticoagulation, venous
gangrene may be prevented by starting warfarin simulta-
neously with LMWH at small dose e.g. 5 mg, as large doses
with lead to rapid increase in INR leading to depletion of
protein C and subsequent venous gangrene [30].
A recent systemic review of clinical trails concluded that
Low-molecular-weight heparin (LMWH) is modestly
superior to unfractionated heparin at preventing recurrent
DVT and is at least as effective as unfractionated heparin
for treatment of pulmonary embolism [31]. LMWH is
associated with a lower risk of bleeding, safe use in an out-
patient setting without the need for laboratory monitor-
Table 2: Prevention of VTE and VG in cancer patients
General measures: attention to good nutrition, hydration and mobilisation
Physical/mechanical measures: TEDS (Thromboembolic Deterrent Stockings) And intermittent pneumatic compression Stocking during 
surgical operations
Pharmacologic measures: LMWH, UFH Starting warfarin at low dose simultaneously with LMWH in case of established VTE
Table 1: Predisposing factors for developing venous thrombosis and gangrene in cancer patients
• Supra-therapeutic level of INR ≥ 6.0
• *Acquired Protein C and protein S deficiency as result of warfarin treatment
• *Heparin induced thrombocytopenia, after initiating or continuing warfarin therapy
• *Cancers of the pancreas, lung, stomach and adenocarcinoma of unknown primary.
• *Positive anticardiolipin antibodies
• *Obesity and metabolic syndrome
• Cancer treatment (chemotherapy or hormonal e.g. tamoxifen)
• Surgical operations
*Risk of recurrent thromboembolismPage 3 of 5
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thrombocytopenia. Interestingly, recent evidence from
randomised trails (FAMOUS and CLOT trails) have sug-
gested that LMWH may have anti-neoplastic effects and
there is increased survival with its used in patients with
advanced solid tumours [32,33].
In a case of established VG, warfarin should be stopped
and LMWH should be started or continued. It is likely that
LMWH provide potential promise as a safe and effective
measure in the management of such patients [34]. Impor-
tantly, other measures such as limb elevation to reduce
oedema and attention to skin care to prevent pressure
sores, infection and wet gangrene cannot be overempha-
sised. In acute iliofemoral DVT venous thrombectomy,
intrathrombus catheter-directed thrombolysis, and phar-
macomechanical thrombolysis can be used to successfully
remove venous thrombus with increasing safety [35]
(table 3). On the other hand, in cases of proven HIT alter-
native anticoagulation such as direct thrombin inhibitors
(DTI) e.g. hirudin or argatroban can be used [36] (table 2,
3).
Conclusion
Venous gangrene is rare in association with malignancy.
The pathogenesis is complex and involves a series of dif-
ferent mechanisms. Hypercoagulable state associated with
malignancy and associated increase or decrease in clotting
factors, cancer treatment, prolonged immobilisation, sur-
gical operations and metabolic syndrome are all associ-
ated with increased risk of VG. The current evidence
suggests that LMWH is the drug of choice in the treatment
of venous thromboembolism and gangrene. It is safe and
effective and associated with lower risk of bleeding, fewer
recurrent VTE, lower risk of HIT and venous gangrene in
comparison with UFH and Vitamin K antagonists. Further
research will reveal the complex mechanisms and provide
evidence for safe and effective treatment.
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